Alyeska Investment Group L.P. Acquires New Shares in GSK PLC Sponsored ADR $GSK

Key Points

• Alyeska Investment Group L.P. acquired a new position in GSK PLC by purchasing 1,736,358 shares valued at approximately $67.3 million during the 1st quarter.
• The company reported Q2 earnings of $1.23 per share, exceeding analysts' expectations, with a revenue of $10.64 billion, significantly higher than the consensus estimate of $7.92 billion.
• GSK has announced a quarterly dividend of $0.4206, resulting in an annualized dividend yield of 4.3%, though it's important to note that the company recently cut its dividend payout ratio to 77.78%.

Alyeska Investment Group L.P. bought a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 1,736,358 shares of the pharmaceutical company's stock, valued at approximately $67,267,000. Alyeska Investment Group L.P. owned 0.08% of GSK at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Kingsview Wealth Management LLC grew its position in GSK by 1.8% during the first quarter. Kingsview Wealth Management LLC now owns 15,227 shares of the pharmaceutical company's stock worth $590,000 after buying an additional 271 shares in the last quarter. Rehmann Capital Advisory Group grew its position in GSK by 4.6% during the first quarter. Rehmann Capital Advisory Group now owns 6,407 shares of the pharmaceutical company's stock worth $248,000 after buying an additional 279 shares in the last quarter. First PREMIER Bank grew its position in GSK by 6.5% during the first quarter. First PREMIER Bank now owns 4,659 shares of the pharmaceutical company's stock worth $181,000 after buying an additional 286 shares in the last quarter. Northwest Bank & Trust Co grew its position in GSK by 1.3% during the fourth quarter. Northwest Bank & Trust Co now owns 22,405 shares of the pharmaceutical company's stock worth $765,000 after buying an additional 289 shares in the last quarter. Finally, OneAscent Financial Services LLC grew its position in GSK by 3.9% during the first quarter. OneAscent Financial Services LLC now owns 7,700 shares of the pharmaceutical company's stock worth $297,000 after buying an additional 292 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company's stock.

GSK Price Performance

Shares of GSK stock traded up $0.73 during trading hours on Tuesday, reaching $40.78. The company's stock had a trading volume of 2,124,565 shares, compared to its average volume of 5,056,891. The firm's 50 day simple moving average is $38.55 and its 200-day simple moving average is $38.38. The company has a market capitalization of $83.06 billion, a price-to-earnings ratio of 18.88, a PEG ratio of 2.03 and a beta of 0.53. GSK PLC Sponsored ADR has a fifty-two week low of $31.72 and a fifty-two week high of $44.19. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company's revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Sell-side analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be issued a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.1%. GSK's dividend payout ratio (DPR) is 77.78%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on GSK shares. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a research report on Friday. Berenberg Bank reissued a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and an average price target of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.